178 related articles for article (PubMed ID: 9579234)
1. Carrier status for steroid 21-hydroxylase deficiency is only one factor in the variable phenotype of acne.
Ostlere LS; Rumsby G; Holownia P; Jacobs HS; Rustin MH; Honour JW
Clin Endocrinol (Oxf); 1998 Feb; 48(2):209-15. PubMed ID: 9579234
[TBL] [Abstract][Full Text] [Related]
2. Hormonal evaluation and mutation screening for steroid 21-hydroxylase deficiency in patients with unilateral and bilateral adrenal incidentalomas.
Patócs A; Tóth M; Barta C; Sasvári-Székely M; Varga I; Szücs N; Jakab C; Gláz E; Rácz K
Eur J Endocrinol; 2002 Sep; 147(3):349-55. PubMed ID: 12213672
[TBL] [Abstract][Full Text] [Related]
3. Adrenal 21-hydroxylase gene mutations in Slovenian hyperandrogenic women: evaluation of corticotrophin stimulation and HLA polymorphisms in screening for carrier status.
Dolzan V; Prezelj J; Vidan-Jeras B; Breskvar K
Eur J Endocrinol; 1999 Aug; 141(2):132-9. PubMed ID: 10427156
[TBL] [Abstract][Full Text] [Related]
4. Hyperandrogenism in carriers of CYP21 mutations: the role of genotype.
Admoni O; Israel S; Lavi I; Gur M; Tenenbaum-Rakover Y
Clin Endocrinol (Oxf); 2006 Jun; 64(6):645-51. PubMed ID: 16712666
[TBL] [Abstract][Full Text] [Related]
5. Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism.
Knochenhauer ES; Cortet-Rudelli C; Cunnigham RD; Conway-Myers BA; Dewailly D; Azziz R
J Clin Endocrinol Metab; 1997 Feb; 82(2):479-85. PubMed ID: 9024240
[TBL] [Abstract][Full Text] [Related]
6. Variable ACTH-stimulated 17-hydroxyprogesterone values in 21-hydroxylase deficiency carriers are not related to the different CYP21 gene mutations.
Bachega TA; Brenlha EM; Billerbeck AE; Marcondes JA; Madureira G; Arnhold IJ; Mendonca BB
J Clin Endocrinol Metab; 2002 Feb; 87(2):786-90. PubMed ID: 11836321
[TBL] [Abstract][Full Text] [Related]
7. The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations.
Escobar-Morreale HF; San Millán JL; Smith RR; Sancho J; Witchel SF
Fertil Steril; 1999 Oct; 72(4):629-38. PubMed ID: 10521100
[TBL] [Abstract][Full Text] [Related]
8. Refractory acne and 21-hydroxylase deficiency in a selected group of female patients.
Caputo V; Fiorella S; Curiale S; Caputo A; Niceta M
Dermatology; 2010; 220(2):121-7. PubMed ID: 20110635
[TBL] [Abstract][Full Text] [Related]
9. 17-Hydroxyprogesterone in children, adolescents and adults.
Honour JW
Ann Clin Biochem; 2014 Jul; 51(Pt 4):424-40. PubMed ID: 24711560
[TBL] [Abstract][Full Text] [Related]
10. Genotype-phenotype analysis in late onset 21-hydroxylase deficiency in comparison to the classical forms.
Rumsby G; Avey CJ; Conway GS; Honour JW
Clin Endocrinol (Oxf); 1998 Jun; 48(6):707-11. PubMed ID: 9713558
[TBL] [Abstract][Full Text] [Related]
11. Molecular abnormalities of the 21-hydroxylase gene in hyperandrogenic women with an exaggerated 17-hydroxyprogesterone response to short-term adrenal stimulation.
Azziz R; Owerbach D
Am J Obstet Gynecol; 1995 Mar; 172(3):914-8. PubMed ID: 7892885
[TBL] [Abstract][Full Text] [Related]
12. Exhaustive screening of the 21-hydroxylase gene in a population of hyperandrogenic women.
Blanché H; Vexiau P; Clauin S; Le Gall I; Fiet J; Mornet E; Dausset J; Bellanné-Chantelot C
Hum Genet; 1997 Nov; 101(1):56-60. PubMed ID: 9385370
[TBL] [Abstract][Full Text] [Related]
13. Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency.
Weintrob N; Brautbar C; Pertzelan A; Josefsberg Z; Dickerman Z; Kauschansky A; Lilos P; Peled D; Phillip M; Israel S
Eur J Endocrinol; 2000 Sep; 143(3):397-403. PubMed ID: 11022183
[TBL] [Abstract][Full Text] [Related]
14. Augmented 17 alpha-hydroxyprogesterone response to ACTH stimulation as evidence of decreased 21-hydroxylase activity in patients with incidentally discovered adrenal tumours ('incidentalomas').
Seppel T; Schlaghecke R
Clin Endocrinol (Oxf); 1994 Oct; 41(4):445-51. PubMed ID: 7955456
[TBL] [Abstract][Full Text] [Related]
15. Mutational spectrum of steroid 21-hydroxylase and the genotype-phenotype association in Middle European patients with congenital adrenal hyperplasia.
Dolzan V; Sólyom J; Fekete G; Kovács J; Rakosnikova V; Votava F; Lebl J; Pribilincova Z; Baumgartner-Parzer SM; Riedl S; Waldhauser F; Frisch H; Stopar-Obreza M; Krzisnik C; Battelino T
Eur J Endocrinol; 2005 Jul; 153(1):99-106. PubMed ID: 15994751
[TBL] [Abstract][Full Text] [Related]
16. Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency.
Kösel S; Burggraf S; Fingerhut R; Dörr HG; Roscher AA; Olgemöller B
Clin Chem; 2005 Feb; 51(2):298-304. PubMed ID: 15608154
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of 21-hydroxylase deficiency in adrenal incidentalomas - hormonal and mutation screening.
Wagnerova H; Lazúrová I; Habalová V; Dudásová D; Vrzgula A
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):272-5. PubMed ID: 18589890
[TBL] [Abstract][Full Text] [Related]
18. The frequency of CYP 21 gene mutations in Turkish women with hyperandrogenism.
Kelestimur F; Everest H; Dundar M; Tanriverdi F; White C; Witchel SF
Exp Clin Endocrinol Diabetes; 2009 May; 117(5):205-8. PubMed ID: 19085698
[TBL] [Abstract][Full Text] [Related]
19. Limited value of serum steroid measurements in identification of mild form of 21-hydroxylase deficiency.
Török D; Halász Z; Garami M; Homoki J; Fekete G; Sólyom J
Exp Clin Endocrinol Diabetes; 2003 Feb; 111(1):27-32. PubMed ID: 12605347
[TBL] [Abstract][Full Text] [Related]
20. Classical and nonclassical 21-hydroxylase deficiency: a molecular study of Argentine patients.
Dain LB; Buzzalino ND; Oneto A; Belli S; Stivel M; Pasqualini T; Minutolo C; Charreau EH; Alba LG
Clin Endocrinol (Oxf); 2002 Feb; 56(2):239-45. PubMed ID: 11874416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
